WHO suspends hydroxychloroquine trial for second time The World Health Organization (WHO) on Saturday said it stopped a clinical trial of the anti-malaria drug hydroxychloroquine to treat coronavirus disease 2019 (Covid-19) patients.
“WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ ritonavir arms,” the WHO said in a statement. “The Solidarity Trial was established by WHO to find an effective Covid-19 treatment for hospitalized patients.”
In May, the WHO said that due to safety concerns, it was temporarily halting a clinical trial of hydroxychloroquine for Covid-19 patients. Since first appearing in Wuhan, China last December, the coronavirus disease has spread to at least 188 countries and regions.
The US, Brazil and Russia are The organization said that currently the countries hardest hit in the world. according to interim trial results, “hydroxychloroquine and lopinavir/ The pandemic has killed more ritonavir produce little or no reduction than 528,200 people worldwide, with an in the mortality of hospitalized Covid-19 excess of 11.1 million confirmed cases patients when compared to standard and greater than 6 million recoveries, of care. Solidarity trial investigators according to figures compiled by will interrupt the trials with immediate US-based Johns Hopkins University. (Anadolu) effect.” July 4-10, 2020 |
59
